Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WS016 in Patients With Hyperkalemia
NCT07881965Phase 3Recruiting
- Sponsor
- Waterstone Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
A Phase 3 trial of WS016 in hyperkalemia, sponsored by Waterstone Pharmaceuticals. Started Sep 2026; status: recruiting.
02
Drugs
WS016
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT07881965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881965.